Ameriprise Financial Inc. Has $442.37 Million Stock Holdings in McKesson Corporation $MCK

Ameriprise Financial Inc. lifted its stake in shares of McKesson Corporation (NYSE:MCK) by 33.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 572,569 shares of the company’s stock after acquiring an additional 144,869 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.46% of McKesson worth $442,368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. J.W. Cole Advisors Inc. boosted its position in McKesson by 35.3% during the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares during the last quarter. Private Wealth Partners LLC raised its position in shares of McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after acquiring an additional 1,682 shares in the last quarter. AlphaQuest LLC raised its position in shares of McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after acquiring an additional 843 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after purchasing an additional 36,451 shares during the period. Finally, CW Advisors LLC lifted its stake in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after purchasing an additional 8,130 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,868 shares of company stock worth $3,743,820 in the last ninety days. 0.08% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

MCK has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Mizuho boosted their price target on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research note on Thursday, February 5th. Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Raymond James Financial set a $970.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Finally, TD Cowen lifted their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $960.93.

McKesson Stock Performance

MCK stock opened at $941.51 on Monday. The stock’s 50 day simple moving average is $893.90 and its 200 day simple moving average is $826.35. The company has a market cap of $115.33 billion, a P/E ratio of 27.08, a price-to-earnings-growth ratio of 1.51 and a beta of 0.38. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm posted $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities analysts predict that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.